EMA grants orphan drug designation to AlloVir’s Viralym-M

This article was originally published here

Viralym-M is the company’s lead allogeneic, off-the-shelf, multi-virus specific T-cell therapy, being developed for the treatment and prevention of serious viral diseases caused by six commonly occurring, devastating

The post EMA grants orphan drug designation to AlloVir’s Viralym-M appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply